Literature DB >> 15734645

Structural basis for the highly selective inhibition of MMP-13.

Christian K Engel1, Bernard Pirard, Sandra Schimanski, Reinhard Kirsch, Jörg Habermann, Otmar Klingler, Volkhard Schlotte, Klaus Ulrich Weithmann, K Ulrich Wendt.   

Abstract

Inhibitors for matrix metalloproteinases (MMPs) are under investigation for the treatment of cancer, arthritis, and cardiovascular disease. Here, we report a class of highly selective MMP-13 inhibitors (pyrimidine dicarboxamides) that exhibit no detectable activity against other MMPs. The high-resolution X-ray structures of three molecules of this series bound to MMP-13 reveal a novel binding mode characterized by the absence of interactions between the inhibitors and the catalytic zinc. The inhibitors bind in the S1' pocket and extend into an additional S1' side pocket, which is unique to MMP-13. We analyze the determinants for selectivity and describe the rational design of improved compounds with low nanomolar affinity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15734645     DOI: 10.1016/j.chembiol.2004.11.014

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  57 in total

Review 1.  Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility.

Authors:  György Dormán; Sándor Cseh; István Hajdú; László Barna; Dénes Kónya; Krisztina Kupai; László Kovács; Péter Ferdinandy
Journal:  Drugs       Date:  2010-05-28       Impact factor: 9.546

Review 2.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

3.  Activity of ADAM17 (a disintegrin and metalloprotease 17) is regulated by its noncatalytic domains and secondary structure of its substrates.

Authors:  Roma Stawikowska; Mare Cudic; Marc Giulianotti; Richard A Houghten; Gregg B Fields; Dmitriy Minond
Journal:  J Biol Chem       Date:  2013-06-18       Impact factor: 5.157

4.  Binary image representation of a ligand binding site: its application to efficient sampling of a conformational ensemble.

Authors:  Edon Sung; Sangsoo Kim; Whanchul Shin
Journal:  BMC Bioinformatics       Date:  2010-05-18       Impact factor: 3.169

5.  Molecular docking and inhibition of matrix metalloproteinase-2 by novel difluorinatedbenzylidene curcumin analog.

Authors:  Aamir Ahmad; Afreen Sayed; Kevin R Ginnebaugh; Vivek Sharma; Anita Suri; Arundhati Saraph; Subhash Padhye; Fazlul H Sarkar
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

6.  Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.

Authors:  Joshua Roth; Dmitriy Minond; Etzer Darout; Qin Liu; Janelle Lauer; Peter Hodder; Gregg B Fields; William R Roush
Journal:  Bioorg Med Chem Lett       Date:  2011-09-22       Impact factor: 2.823

7.  Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation.

Authors:  Robert H Scannevin; Richard Alexander; Tara Mezzasalma Haarlander; Sharon L Burke; Monica Singer; Cuifen Huo; Yue-Mei Zhang; Diane Maguire; John Spurlino; Ingrid Deckman; Karen I Carroll; Frank Lewandowski; Eric Devine; Keli Dzordzorme; Brett Tounge; Cindy Milligan; Shariff Bayoumy; Robyn Williams; Celine Schalk-Hihi; Kristi Leonard; Paul Jackson; Matthew Todd; Lawrence C Kuo; Kenneth J Rhodes
Journal:  J Biol Chem       Date:  2017-08-31       Impact factor: 5.157

8.  Hydroxamate-Based Selective Macrophage Elastase (MMP-12) Inhibitors and Radiotracers for Molecular Imaging.

Authors:  Kiran Gona; Jakub Toczek; Yunpeng Ye; Nowshin Sanzida; Arvene Golbazi; Parnaz Boodagh; Mani Salarian; Jae-Joon Jung; Saranya Rajendran; Gunjan Kukreja; Terence L Wu; Laurent Devel; Mehran M Sadeghi
Journal:  J Med Chem       Date:  2020-11-18       Impact factor: 7.446

9.  Ligand-induced expansion of the S1' site in the anthrax toxin lethal factor.

Authors:  Kimberly M Maize; Elbek K Kurbanov; Rodney L Johnson; Elizabeth Ambrose Amin; Barry C Finzel
Journal:  FEBS Lett       Date:  2015-11-11       Impact factor: 4.124

10.  A Cycloaddition Strategy for Use toward Berkelic Acid, an MMP Inhibitor and Potent Anticancer Agent Displaying a Unique Chroman Spiroketal Motif.

Authors:  Yaodong Huang; Thomas R R Pettus
Journal:  Synlett       Date:  2008-05-11       Impact factor: 2.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.